Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia

C.J. van den Hurk, E.M. van den Akker-van Marle, W.P.M. Breed, L.V. van de Poll-Franse, J. Nortier, J.W.W. Coebergh

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Background.
Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover.
Material and methods.
Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36.
Results.
Scalp cooling reduced the use of a wig or head cover by 40%, but wigs were still purchased unnecessarily by 38% of scalp-cooled patients. Average societal costs decreased therefore only by €269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between €20 000 and €40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover.
Conclusion.
Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively.
Original languageEnglish
Pages (from-to)80-87
JournalActa Oncologica
Volume53
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Cost-Benefit Analysis
Quality-Adjusted Life Years
Hair

Cite this

van den Hurk, C. J., van den Akker-van Marle, E. M., Breed, W. P. M., van de Poll-Franse, L. V., Nortier, J., & Coebergh, J. W. W. (2014). Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. Acta Oncologica, 53(1), 80-87. https://doi.org/10.3109/0284186X.2013.794955
van den Hurk, C.J. ; van den Akker-van Marle, E.M. ; Breed, W.P.M. ; van de Poll-Franse, L.V. ; Nortier, J. ; Coebergh, J.W.W. / Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. In: Acta Oncologica. 2014 ; Vol. 53, No. 1. pp. 80-87.
@article{c1212d7f85a94fbd811de0b7fd814cdd,
title = "Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia",
abstract = "Background. Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover. Material and methods. Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36. Results. Scalp cooling reduced the use of a wig or head cover by 40{\%}, but wigs were still purchased unnecessarily by 38{\%} of scalp-cooled patients. Average societal costs decreased therefore only by €269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between €20 000 and €40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover. Conclusion. Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively.",
author = "{van den Hurk}, C.J. and {van den Akker-van Marle}, E.M. and W.P.M. Breed and {van de Poll-Franse}, L.V. and J. Nortier and J.W.W. Coebergh",
year = "2014",
doi = "10.3109/0284186X.2013.794955",
language = "English",
volume = "53",
pages = "80--87",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "TAYLOR & FRANCIS LTD",
number = "1",

}

van den Hurk, CJ, van den Akker-van Marle, EM, Breed, WPM, van de Poll-Franse, LV, Nortier, J & Coebergh, JWW 2014, 'Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia', Acta Oncologica, vol. 53, no. 1, pp. 80-87. https://doi.org/10.3109/0284186X.2013.794955

Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. / van den Hurk, C.J.; van den Akker-van Marle, E.M.; Breed, W.P.M.; van de Poll-Franse, L.V.; Nortier, J.; Coebergh, J.W.W.

In: Acta Oncologica, Vol. 53, No. 1, 2014, p. 80-87.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia

AU - van den Hurk, C.J.

AU - van den Akker-van Marle, E.M.

AU - Breed, W.P.M.

AU - van de Poll-Franse, L.V.

AU - Nortier, J.

AU - Coebergh, J.W.W.

PY - 2014

Y1 - 2014

N2 - Background. Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover. Material and methods. Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36. Results. Scalp cooling reduced the use of a wig or head cover by 40%, but wigs were still purchased unnecessarily by 38% of scalp-cooled patients. Average societal costs decreased therefore only by €269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between €20 000 and €40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover. Conclusion. Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively.

AB - Background. Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover. Material and methods. Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36. Results. Scalp cooling reduced the use of a wig or head cover by 40%, but wigs were still purchased unnecessarily by 38% of scalp-cooled patients. Average societal costs decreased therefore only by €269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between €20 000 and €40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover. Conclusion. Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively.

U2 - 10.3109/0284186X.2013.794955

DO - 10.3109/0284186X.2013.794955

M3 - Article

VL - 53

SP - 80

EP - 87

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 1

ER -